SCR7, a specific DNA Ligase IV inhibitor, blocks nonhomologous end-joining (NHEJ).

在负荷Dalton's淋巴瘤的Swiss albino小鼠模型中,腹腔注射SCR7（20 mg/kg）不能够消退肿瘤.在BALB/c小鼠体内,腹腔注射SCR7（20 mg/kg）能够增强辐射,依托泊苷和3-氨基苯甲酰胺对于Dalton's淋巴瘤细胞的衍生瘤的细胞毒性作用.

在MCF7细胞（IC50=40 μM）,A549细胞（IC50=34 μM）,HeLa细胞（IC50=44 μM）,T47D细胞（IC50=8.5 μM）,A2780细胞（IC50=120 μM）,HT1080细胞（IC50=10 μM）,和Nalm6细胞（IC50=50 μM）中,SCR7能够显著抑制细胞增殖。

Complementation of SCR7 Inhibition with Puri?ed Ligase IV: Complementation experiment is carried out by adding increasing concentrations of puri?ed Ligase IV/XRCC4 complex (30, 60, and 120 fmol) along with the oligomeric DNA substrates (5' compatible and 5'-5' noncompatible ends) to the SCR7-treatedextracts. Reactions are incubated for 2 h at 25℃. The reaction products are then resolved on 8% denaturing PAGE. The gel is dried and exposed and the signal is detected with a PhosphorImager and analyzed with Multi Gauge (V3.0) software.

SCR7 is dissolved in DMSO and stored, and then diluted with appropriate medium before use[3]. Wild-type, AAVS1TLR HEK293 and mouse NIH3T3 cells are maintained in DMEM supplied with 15% FBS, cells are passaged three times per week. The mouse Burkitt lymphoma cell line, generated from a Burkitt-like mouse lymphoma is maintained in DMEM supplied with 15% FBS, 2 mM HEPES, 2 mM sodium pyruvate, 2 mM L-glutamine, and 1× NAA, beta-mercaptoethanol and passaged four times per week. For puromycin selection, mCherry+ cells are sorted, seeded at 103 cells/well and selected with 3 mg/mL of Puromycin for 2 weeks. Then colonies are counted and single cells are sorted. The SCR7 inhibitor is purchased, 12 h after transfection these cells are maintained in complete medium supplied with 1 mM SCR7 inhibitor until analysis. At SCR7 concentrations of 60 mM and 10 mM, A reduction of transfection efficiency and of cell viability is observed[3].